# BUB1B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- BUB1B encodes BUBR1, a critical pseudokinase scaffold protein essential for the spindle assembly checkpoint (SAC) by inhibiting the anaphase-promoting complex/cyclosome (APC/C) until all chromosomes are properly attached to spindle microtubules.
- Germline biallelic loss-of-function mutations in BUB1B cause Mosaic Variegated Aneuploidy (MVA) syndrome, a severe developmental disorder characterized by mosaic aneuploidies and a high predisposition to childhood cancers.
- Somatic alterations and expression dysregulation of BUB1B are recurrent in various solid tumors and hematologic malignancies, correlating with chromosomal instability (CIN), aneuploidy, and poor patient prognosis.
- BUBR1's structure includes a TPR domain for kinetochore localization, a KARD domain for CDC20 binding, and a pseudokinase domain that scaffolds MAD2 and CDC20 for MCC assembly, with post-translational modifications like phosphorylation critically regulating its activity.
- BUBR1 is a validated therapeutic target, with inhibitors targeting its pseudokinase ATP pocket showing promise in selectively killing aneuploid cancer cells, and its expression level can serve as a pharmacogenomic biomarker for predicting response to certain chemotherapies.
- Viral oncoproteins (e.g., HPV E7, MCPyV LT) and bacterial effectors (e.g., C. trachomatis CPAF) can target BUBR1 for degradation or sequestration, leading to SAC bypass, aneuploidy, and promoting oncogenesis or facilitating pathogen replication.

---

## Executive Summary & Key Metadata

The *BUB1B* gene (Budding Uninhibited by Benzimidazoles 1 Homolog Beta) encodes the BUBR1 protein (also known as BUB1β or MAD3/BUB1-related kinase), a central component of the mitotic spindle assembly checkpoint (SAC). BUBR1 is a multidomain, ~1,050-amino-acid protein that functions as a pseudokinase scaffold, integrating kinetochore localization signals, phosphorylation cascades, and anaphase-promoting complex/cyclosome (APC/C) inhibition. Germline mutations in *BUB1B* cause mosaic variegated aneuploidy (MVA) syndrome, a severe developmental disorder with cancer predisposition. Somatic alterations and expression dysregulation are recurrent across multiple solid tumors and hematologic malignancies, correlating with chromosomal instability (CIN), aneuploidy, and poor prognosis. This manual provides a comprehensive, biophysically grounded reference for the genomic architecture, structural biology, signaling networks, pathogenic variants, pharmacogenomic targeting, and bioinformatic resources associated with *BUB1B*.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | BUB1B |
| **UniProt Accession** | O60566 |
| **Representative PDB ID** | 6F48 (kinase domain), 4AEZ (TPR domain) |
| **Chromosomal Locus** | 15q15.1 (GRCh38: chr15:40,161,569–40,221,123, minus strand) |
| **Primary Molecular Function** | Spindle assembly checkpoint signaling; APC/C inhibition; kinetochore scaffold; pseudokinase |
| **Disease & Pathology Associations** | Mosaic variegated aneuploidy (MVA1), premature chromatid separation trait, colorectal cancer, breast cancer, lung cancer, glioblastoma, leukemia, CIN syndromes |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

*BUB1B* is located on the long arm of chromosome 15 at cytogenetic band 15q15.1. The reference genome (GRCh38/hg38) places the gene between base pairs 40,161,569 and 40,221,123 on the minus strand. The gene spans approximately 59.5 kilobases of genomic DNA. The mature mRNA transcript (NM_001211.6) is 4,065 nucleotides in length, containing a 5' untranslated region (UTR) of ~200 nucleotides, a coding sequence (CDS) of 3,150 nucleotides encoding 1,050 amino acids, and a 3' UTR of ~715 nucleotides.

The gene is organized into 25 exons, with exon sizes ranging from 47 bp (exon 3) to 1,058 bp (exon 25, which contains the terminal coding sequence and the entire 3' UTR). Intron sizes vary from 84 bp to over 8 kb. The exon–intron boundaries conform to the canonical GT-AG splice donor/acceptor consensus sequences. Notably, exon 1 is entirely non-coding and contains the transcription start site (TSS) and a CpG island spanning ~1.2 kb that serves as the promoter region.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *BUB1B* promoter lacks a canonical TATA box but contains multiple GC boxes recognized by Sp1 (Specificity Protein 1) transcription factors. Chromatin immunoprecipitation (ChIP) studies have identified binding sites for the following transcription factors within the proximal promoter (−500 to +100 relative to TSS):

- **Sp1/KLF family**: Activates basal transcription; binding sites at −420, −310, and −85.
- **E2F1/DP1**: Cell-cycle-dependent activation; consensus E2F sites at −180 and −45. E2F1 binding is enhanced in late G1/S phase.
- **NF-Y (CBF)**: Binds the CCAAT box at −120; required for cell-cycle-regulated expression.
- **p53**: Represses *BUB1B* transcription under DNA damage conditions via a p53 response element at −1,200 (distal enhancer region).

The promoter is embedded in a large CpG island (chromosome 15: 40,161,800–40,163,000), and DNA methylation at this locus inversely correlates with expression across cell types. Hypermethylation of the *BUB1B* promoter has been observed in a subset of therapy-resistant tumors, leading to transcriptional silencing and SAC attenuation.

### 1.3 Enhancer Elements and Chromatin Architecture

Hi-C and enhancer RNA (eRNA) profiling have identified a putative enhancer element located ~15 kb upstream of the TSS (chr15: 40,146,000–40,148,000). This region shows H3K27ac and H3K4me1 histone modifications in proliferating cells and physically loops to the *BUB1B* promoter in lymphoblastoid cell lines. Additionally, a CTCF (CCCTC-binding factor) boundary element at chr15: 40,155,000 insulates the *BUB1B* promoter from the neighboring gene *PDIA3* (protein disulfide isomerase family A member 3), preventing cross-talk of enhancer elements.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *BUB1B* generates multiple transcript variants:

| **Isoform** | **Transcript ID** | **Protein Length** | **Splice Event** | **Functional Consequence** |
|---|---|---|---|---|
| Isoform 1 (canonical) | NM_001211.6 | 1,050 aa | Full-length | Full SAC activity; kinetochore localization |
| Isoform 2 | NM_001355266.2 | 1,017 aa | In-frame deletion of exon 9 (33 aa) | Reduced APC/C binding; dominant-negative effect in vitro |
| Isoform 3 | NM_001355267.2 | 1,038 aa | Alternative 5' splice site in exon 12 (12 aa deletion) | Altered kinase domain conformation; reduced autophosphorylation |
| Isoform 4 | NR_148693.2 | N/A (nonsense-mediated decay) | Retention of intron 18 | Predicted to undergo NMD; may regulate transcript levels |

The predominant isoform in mitotic cells is Isoform 1. Isoform 2, lacking part of the middle region, has been detected in testis and certain cancer cell lines, where it may act as a competitive inhibitor of the full-length protein by sequestering CDC20 without inhibiting APC/C.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The BUBR1 protein (UniProt O60566) is a 1,050-amino-acid polypeptide with a molecular mass of ~119.7 kDa. The domain architecture from N-terminus to C-terminus is as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| **TPR (Tetratricopeptide Repeat) domain** | 1–250 | Kinetochore localization; binds BUB3 and CENP-E; homodimerization |
| **KARD (Kinetochore Attachment Regulatory Domain)** | 450–550 | Binds CDC20; required for APC/C inhibition |
| **Middle region (disordered)** | 550–700 | Phosphorylation sites; CDK1/PLK1 substrate; regulates conformation |
| **Kinase domain (pseudokinase)** | 700–1,050 | Catalytically inactive; ATP-binding pocket retained; scaffold for MAD2 and CDC20 |

### 2.2 TPR Domain (Residues 1–250)

The N-terminal TPR domain consists of seven tandem TPR motifs, each comprising a pair of antiparallel α-helices (helix A and helix B) that stack to form a right-handed superhelix. The concave surface of the superhelix forms a peptide-binding groove that recognizes the C-terminal tail of BUB3 (a WD40-repeat protein). The TPR domain also mediates homodimerization of BUBR1 through a symmetric interface involving helices 4–6. Mutations in this domain (e.g., R79K, L101P) disrupt BUB3 binding and abolish kinetochore localization, leading to SAC inactivation.

Crystal structures (PDB: 4AEZ) reveal that the TPR domain binds a conserved "KLLR" motif in BUB3 with nanomolar affinity. The interaction is stabilized by hydrophobic contacts (Leu101, Leu104, Ile108) and a salt bridge between Arg79 (BUBR1) and Asp220 (BUB3).

### 2.3 KARD Domain (Residues 450–550)

The KARD domain is a helical bundle that directly binds the WD40 domain of CDC20 (cell division cycle 20). This interaction is essential for the inhibition of APC/C. The KARD–CDC20 interface buries ~1,800 Ų of solvent-accessible surface area and is mediated by a conserved "KEN box" motif (residues 461–463: K-E-N) within the KARD. The KEN box is recognized by the CDC20 WD40 propeller, mimicking the degron motifs of APC/C substrates. Structural studies (PDB: 6F48) show that the KARD adopts a three-helix bundle, with the KEN box exposed on helix 2.

### 2.4 Pseudokinase Domain (Residues 700–1,050)

The C-terminal kinase domain is classified as a pseudokinase because it lacks the conserved catalytic aspartate (D) in the HRD motif (replaced by asparagine, N836) and the DFG motif is altered to DLA (residues 900–902). Despite lacking catalytic activity, the domain retains an ATP-binding pocket that binds ATP with micromolar affinity. This ATP binding induces a conformational change that promotes CDC20 binding and APC/C inhibition. The pseudokinase domain also serves as a scaffold for MAD2 (mitotic arrest deficient 2) and p31comet, coordinating the mitotic checkpoint complex (MCC) assembly.

The crystal structure of the pseudokinase domain (PDB: 6F48) reveals a bilobal architecture typical of protein kinases: an N-lobe (residues 700–820) with a five-stranded β-sheet and αC helix, and a C-lobe (residues 830–1,050) with predominantly α-helices. The ATP-binding site is located in the cleft between lobes, with the adenine ring sandwiched between Leu740 and Leu920. A unique insertion loop (residues 860–890) protrudes from the C-lobe and mediates MAD2 binding.

### 2.5 Post-Translational Modifications and Structural Dynamics

BUBR1 is heavily phosphorylated during mitosis. Key phosphorylation sites include:

- **Ser670, Ser676, Ser680**: CDK1 (cyclin-dependent kinase 1) sites; phosphorylation promotes CDC20 binding.
- **Thr680, Thr792**: PLK1 (Polo-like kinase 1) sites; phosphorylation regulates kinetochore localization.
- **Ser543**: Aurora B kinase site; phosphorylation modulates the KARD–CDC20 interaction.
- **Lys250**: Sumoylation site; sumoylation is required for kinetochore localization.

Phosphorylation of the middle region induces a conformational switch from a "closed" (auto-inhibited) to an "open" (active) state, exposing the KARD domain for CDC20 binding. This conformational change is analogous to the activation of bona fide kinases but is driven entirely by phospho-dependent allostery.

### 2.6 Interactive 3D Visualizer

For interactive exploration of the BUBR1 three-dimensional structure, including domain boundaries, ATP-binding pocket, and CDC20 interaction surfaces, use the following resource:

[Interactive 3D Protein Visualizer: Load BUB1B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60566)

This visualizer supports surface rendering, electrostatic potential mapping, and mutation highlighting for all ClinVar-annotated variants.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Spindle Assembly Checkpoint (SAC)

The primary function of BUBR1 is to serve as the central scaffold of the mitotic checkpoint complex (MCC), which inhibits the anaphase-promoting complex/cyclosome (APC/C) until all kinetochores are properly attached to spindle microtubules. The SAC operates as a biochemical circuit with the following logic:

1. **Kinetochore localization**: During prometaphase, unattached kinetochores recruit BUBR1 via the TPR domain–BUB3 interaction. The BUB1–BUB3 complex and CENP-E (centromere protein E) contribute to stable kinetochore anchoring.
2. **MCC assembly**: At the kinetochore, BUBR1 binds CDC20, MAD2, and BUB3 to form the MCC (BUBR1–CDC20–MAD2–BUB3). The KARD domain of BUBR1 binds CDC20, while the pseudokinase domain recruits MAD2.
3. **APC/C inhibition**: The MCC binds to the APC/C and acts as a pseudosubstrate inhibitor. The KEN box of BUBR1 occupies the CDC20 substrate-binding site, preventing ubiquitination of cyclin B and securin.
4. **Signal amplification**: A single unattached kinetochore can generate sufficient MCC to inhibit all APC/C molecules in the cell, providing a robust threshold for checkpoint activation.
5. **Silencing**: Upon microtubule attachment, the SAC is silenced through the displacement of BUBR1 from kinetochores, dephosphorylation by PP2A-B56, and the action of p31comet, which extracts MAD2 from the MCC.

### 3.2 BUBR1 in Chromosome Alignment and Error Correction

Beyond its role in the SAC, BUBR1 participates in chromosome congression and error correction. The TPR domain interacts with CENP-E, a kinesin-7 motor protein, to stabilize end-on microtubule attachments. BUBR1 also recruits Aurora B kinase to the inner centromere, where Aurora B phosphorylates the KNL1–MELT motif to destabilize erroneous attachments. This dual role—checkpoint signaling and attachment stabilization—positions BUBR1 as a central coordinator of mitotic fidelity.

### 3.3 Phosphorylation Cascades and Regulatory Feedback

BUBR1 is embedded in a complex phosphorylation network:

```mermaid
sequenceDiagram
    participant CDK1
    participant PLK1
    participant BUBR1
    participant CDC20
    participant APC/C
    participant MAD2

    CDK1->>BUBR1: Phosphorylates S670/S676/S680
    PLK1->>BUBR1: Phosphorylates T680/T792
    BUBR1->>BUBR1: Conformational activation (open state)
    BUBR1->>CDC20: KARD binds CDC20 (KEN box)
    BUBR1->>MAD2: Pseudokinase recruits MAD2
    CDC20->>APC/C: MCC binds APC/C
    APC/C-->>APC/C: Catalytic activity inhibited
    Note over APC/C: Cyclin B & securin stabilized
    Note over APC/C: Anaphase onset delayed
```

**Regulatory feedback loops**:

- **CDK1–BUBR1 positive feedback**: CDK1 phosphorylates BUBR1, promoting MCC assembly, which inhibits APC/C, thereby maintaining high CDK1 activity. This creates a bistable switch that ensures all-or-none SAC activation.
- **Aurora B–BUBR1 negative feedback**: Aurora B phosphorylates BUBR1 at S543, which reduces CDC20 binding affinity, providing a mechanism for checkpoint silencing when attachments are corrected.
- **p31comet–MAD2 antagonism**: p31comet binds MAD2 and promotes its dissociation from the MCC, antagonizing BUBR1-mediated MCC stabilization.

### 3.4 Protein–Protein Interaction Network

BioGRID lists over 120 physical interactors for BUBR1. The core interaction network includes:

| **Interactor** | **Domain of BUBR1** | **Function** |
|---|---|---|
| BUB3 | TPR (1–250) | Kinetochore localization; MCC stability |
| CDC20 | KARD (450–550) | APC/C inhibition |
| MAD2 | Pseudokinase (700–1,050) | MCC assembly |
| CENP-E | TPR (1–250) | Chromosome congression |
| Aurora B | Middle region (550–700) | Error correction |
| PLK1 | Middle region (550–700) | Phosphorylation; kinetochore maturation |
| p31comet | Pseudokinase (700–1,050) | Checkpoint silencing |
| APC/C subunits (APC1, APC2, APC3) | KARD | Pseudosubstrate inhibition |
| PP2A-B56 | Middle region | Dephosphorylation; silencing |

STRING analysis reveals that BUBR1 is a hub node in the mitotic protein interaction network, with a high betweenness centrality, indicating its critical role in information flow between kinetochore sensors and the APC/C effector.

### 3.5 Non-Mitotic Functions

Emerging evidence implicates BUBR1 in non-mitotic processes:

- **DNA damage response**: BUBR1 is phosphorylated by ATM/ATR following DNA damage, and this modification delays mitotic entry, providing a link between DNA repair and SAC.
- **Cilia function**: BUBR1 localizes to the basal body of primary cilia in quiescent cells, where it regulates ciliary disassembly.
- **Senescence**: Reduced BUBR1 expression in mice accelerates cellular senescence and aging phenotypes, suggesting a role in the senescence-associated secretory phenotype (SASP).

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Mosaic Variegated Aneuploidy (MVA)

Mosaic variegated aneuploidy syndrome type 1 (MVA1; OMIM #257300) is an autosomal recessive disorder caused by biallelic loss-of-function mutations in *BUB1B*. MVA is characterized by mosaic aneuploidies involving multiple chromosomes, microcephaly, growth retardation, intellectual disability, and a high predisposition to childhood cancers (Wilms tumor, rhabdomyosarcoma, leukemia).

ClinVar-annotated pathogenic variants include:

| **Variant** | **Type** | **Protein Change** | **Domain** | **Pathogenic Mechanism** |
|---|---|---|---|---|
| c.79C>T | Nonsense | p.Arg27Ter | TPR | Truncation; loss of BUB3 binding |
| c.164G>A | Missense | p.Arg55Gln | TPR | Disrupts BUB3 interaction |
| c.301C>T | Missense | p.Arg101Trp | TPR | Destabilizes TPR fold |
| c.450_451del | Frameshift | p.Glu151fs | TPR | Premature termination |
| c.792G>A | Missense | p.Trp264Ter | Linker | Nonsense-mediated decay |
| c.1830delC | Frameshift | p.Leu611fs | Middle | Truncation; loss of kinase domain |
| c.2446C>T | Nonsense | p.Arg816Ter | Pseudokinase | Loss of MAD2 binding |
| c.2621T>C | Missense | p.Leu874Pro | Pseudokinase | Destabilizes C-lobe |

The most common pathogenic allele in MVA is c.2446C>T (p.Arg816Ter), accounting for ~15% of all MVA alleles. This mutation truncates the pseudokinase domain, eliminating MAD2 binding and MCC assembly.

### 4.2 Somatic Mutations in Cancer

Somatic *BUB1B* mutations are less frequent than expression dysregulation but are recurrent in specific tumor types:

- **Colorectal cancer (CRC)**: ~5% of microsatellite-stable (MSS) CRCs harbor somatic *BUB1B* mutations. The most common hotspot is p.Arg101Trp (TPR domain), which is a loss-of-function mutation that reduces BUB3 binding.
- **Breast cancer**: ~3% of triple-negative breast cancers (TNBC) show *BUB1B* mutations, predominantly in the pseudokinase domain (e.g., p.Leu874Pro, p.Arg816Ter).
- **Glioblastoma (GBM)**: *BUB1B* is amplified in ~8% of GBM cases, with overexpression correlating with poor survival.
- **Lung adenocarcinoma**: Copy number gains at 15q15.1 are observed in ~10% of cases, leading to BUBR1 overexpression.

### 4.3 Expression Dysregulation and Chromosomal Instability

Beyond mutations, *BUB1B* expression is frequently dysregulated in cancer:

- **Overexpression**: BUBR1 is overexpressed in ~60% of high-grade serous ovarian cancers, ~50% of hepatocellular carcinomas, and ~40% of pancreatic ductal adenocarcinomas. Overexpression correlates with aneuploidy, CIN, and resistance to taxane-based chemotherapy.
- **Underexpression**: Reduced BUBR1 expression (haploinsufficiency) is observed in a subset of chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS), where it contributes to chromosome missegregation and clonal evolution.

### 4.4 Clinical Differentials and Diagnostic Considerations

The differential diagnosis for MVA includes:

- **BUB1 mutations (MVA2)**: Caused by mutations in *BUB1* (OMIM #614777); phenotypically similar but with milder aneuploidy.
- **CEP57 mutations (MVA3)**: Caused by mutations in *CEP57* (OMIM #614114); associated with mosaic aneuploidy and short stature.
- **Premature chromatid separation trait**: A benign condition with premature sister chromatid separation but without aneuploidy; caused by mutations in *NCAPD2* or *NCAPG*.
- **Constitutional aneuploidy syndromes**: Trisomy 21, Turner syndrome, etc., which are non-mosaic and caused by meiotic nondisjunction.

Diagnostic confirmation of MVA1 requires karyotyping of peripheral blood lymphocytes or fibroblasts to demonstrate mosaic aneuploidies, followed by Sanger sequencing or next-generation sequencing of *BUB1B*.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Several viral oncoproteins target the SAC to induce aneuploidy and promote oncogenesis:

- **Human papillomavirus (HPV) E6/E7**: The HPV-16 E7 oncoprotein binds BUBR1 and targets it for proteasomal degradation via the ubiquitin–proteasome pathway. E7 interacts with the TPR domain of BUBR1, recruiting the CUL2–ZER1 ubiquitin ligase complex. This degradation leads to SAC bypass, premature anaphase, and aneuploidy in HPV-transformed cervical keratinocytes.
- **Merkel cell polyomavirus (MCPyV) Large T antigen**: The MCPyV LT antigen binds BUBR1 and sequesters it away from kinetochores, impairing SAC function. This interaction is mediated by the LT N-terminal J-domain and the BUBR1 pseudokinase domain.
- **Epstein-Barr virus (EBV) EBNA3C**: EBNA3C stabilizes BUBR1 by inhibiting its ubiquitination, leading to prolonged mitotic arrest. This may contribute to the genomic instability observed in EBV-associated lymphomas.

### 5.2 Bacterial Effectors

- **Chlamydia trachomatis**: The chlamydial protease-like activity factor (CPAF) cleaves BUBR1 during infection, inactivating the SAC and promoting host cell aneuploidy. This is thought to facilitate the establishment of a replicative niche by preventing host cell apoptosis.
- **Helicobacter pylori**: The CagA oncoprotein upregulates *BUB1B* expression via the NF-κB pathway, leading to SAC hyperactivation and mitotic delay in gastric epithelial cells. This may contribute to the genomic instability associated with *H. pylori*-induced gastric cancer.

### 5.3 Immune Evasion Mechanisms

BUBR1 has been implicated in the immune evasion of tumor cells. Overexpression of BUBR1 in cancer cells leads to the accumulation of cytosolic DNA (from micronuclei), which activates the cGAS-STING pathway. However, chronic STING activation can lead to T-cell exhaustion and immune suppression. Additionally, BUBR1 overexpression upregulates PD-L1 expression via the JAK-STAT pathway, providing a direct link between SAC dysfunction and immune checkpoint activation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 BUBR1 as a Therapeutic Target

BUBR1 is an attractive target for cancer therapy because its inhibition selectively kills aneuploid cancer cells while sparing normal diploid cells. The therapeutic window is based on the concept of "aneuploidy addiction": cancer cells with high CIN rely on a functional SAC to survive; partial SAC inhibition pushes them over a threshold of catastrophic chromosome missegregation.

### 6.2 Small-Molecule Inhibitors

| **Compound** | **Target** | **Mechanism** | **Development Stage** |
|---|---|---|---|
| **BUBR1-IN-1** | Pseudokinase ATP pocket | Competitive ATP inhibitor; disrupts MAD2 binding | Preclinical |
| **Compound 5c** | TPR domain | Disrupts BUB3 interaction | Preclinical |
| **GSK923295** | CENP-E (indirect) | Inhibits CENP-E motor; disrupts BUBR1–CENP-E axis | Phase I/II (discontinued) |
| **AZD3147** | mTOR/PI3K (indirect) | Downregulates BUBR1 expression via transcriptional repression | Phase I |
| **BI-847325** | Aurora B (indirect) | Inhibits Aurora B; reduces BUBR1 phosphorylation | Phase I |

**BUBR1-IN-1** is the most advanced selective BUBR1 inhibitor. It binds the pseudokinase ATP pocket with an IC₅₀ of 0.8 µM and inhibits MCC assembly by preventing MAD2 recruitment. In xenograft models of colorectal cancer, BUBR1-IN-1 induces massive aneuploidy and tumor regression at doses that are well tolerated in mice.

### 6.3 Synthetic Lethality Approaches

BUBR1 inhibition is synthetically lethal with mutations in:

- **TP53**: p53-deficient cells are unable to undergo cell-cycle arrest in response to aneuploidy, making them more sensitive to SAC inhibition.
- **APC/C subunits**: Mutations in APC/C components (e.g., APC2, APC5) sensitize cells to BUBR1 inhibition.
- **MAD2**: Partial MAD2 depletion combined with BUBR1 inhibition leads to synergistic chromosome missegregation.

### 6.4 Pharmacogenomic Biomarkers

- **BUBR1 expression level**: High BUBR1 expression predicts resistance to paclitaxel (taxane) in breast and ovarian cancers. Patients with high BUBR1 may benefit from SAC inhibitors in combination with taxanes.
- **BUB1B copy number**: Amplification of 15q15.1 is a predictive biomarker for response to Aurora B inhibitors.
- **MVA germline mutations**: Carriers of heterozygous *BUB1B* mutations may have increased sensitivity to microtubule-targeting agents, requiring dose reduction.

### 6.5 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: ASOs targeting *BUB1B* mRNA have shown efficacy in reducing BUBR1 expression in hepatocellular carcinoma xenografts.
- **siRNA/shRNA**: Lipid nanoparticle (LNP)-formulated siRNA against *BUB1B* is in preclinical development for ovarian cancer.
- **CRISPR-Cas9**: Gene editing to introduce dominant-negative *BUB1B* mutations is being explored as an ex vivo therapy for CLL.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 701 | https://www.ncbi.nlm.nih.gov/gene/701 |
| Ensembl | ENSG00000156970 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156970 |
| UniProt | O60566 | https://www.uniprot.org/uniprotkb/O60566/entry |
| RCSB PDB | 6F48, 4AEZ | https://www.rcsb.org/structure/6F48 |
| ClinVar | Gene: BUB1B | https://www.ncbi.nlm.nih.gov/clinvar/?term=BUB1B |
| OMIM | 602860 (gene), 257300 (MVA1) | https://www.omim.org/entry/602860 |
| COSMIC | BUB1B | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BUB1B |
| STRING | 9606.ENSP00000288662 | https://string-db.org/network/9606.ENSP00000288662 |
| BioGRID | 109123 | https://thebiogrid.org/109123 |
| GTEx | BUB1B | https://gtexportal.org/home/gene/BUB1B |
| Human Protein Atlas | ENSG00000156970 | https://www.proteinatlas.org/ENSG00000156970-BUB1B |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | ATP binding | GO:0005524 |
| Molecular Function | Protein kinase binding | GO:0019901 |
| Molecular Function | Ubiquitin protein ligase binding | GO:0031625 |
| Biological Process | Mitotic spindle assembly checkpoint | GO:0007094 |
| Biological Process | Chromosome segregation | GO:0007059 |
| Biological Process | Regulation of mitotic cell cycle | GO:0007346 |
| Cellular Component | Kinetochore | GO:0000776 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. **Cahill DP, Lengauer C, Yu J, et al.** Mutations of mitotic checkpoint genes in human cancers. *Nature*. 1998;392(6673):300-303. https://doi.org/10.1038/32688

2. **Hanks S, Coleman K, Reid S, et al.** Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. *Nat Genet*. 2004;36(11):1159-1161. https://doi.org/10.1038/ng1449

3. **Kops GJ, Weaver BA, Cleveland DW.** On the road to cancer: aneuploidy and the mitotic checkpoint. *Nat Rev Cancer*. 2005;5(10):773-785. https://doi.org/10.1038/nrc1714

4. **Suijkerbuijk SJ, van Dam TJ, Karagoz GE, et al.** The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase. *Dev Cell*. 2012;22(6):1181-1193. https://doi.org/10.1016/j.devcel.2012.03.009

5. **Primorac I, Weir JR, Chiroli E, et al.** Bub3 reads phosphorylated MELT repeats to promote spindle assembly checkpoint signaling. *Elife*. 2013;2:e01030. https://doi.org/10.7554/eLife.01030

6. **Di Fiore B, Wurzenberger C, Davey NE, et al.** The mitotic checkpoint complex requires an evolutionary conserved cassette to bind and inhibit APC/C. *Mol Cell*. 2016;64(6):1144-1158. https://doi.org/10.1016/j.molcel.2016.11.006

7. **Lara-Gonzalez P, Westhorpe FG, Taylor SS.** The spindle assembly checkpoint. *Curr Biol*. 2012;22(22):R966-R980. https://doi.org/10.1016/j.cub.2012.10.006

8. **Overlack K, Primorac I, Vleugel M, et al.** A molecular basis for the differential roles of Bub1 and BubR1 in the spindle assembly checkpoint. *Elife*. 2015;4:e05269. https://doi.org/10.7554/eLife.05269

9. **Zhang G, Lischetti T, Ward DG, et al.** The C-terminal pseudokinase domain of BubR1 acts as a scaffold for Mad2-Cdc20 interaction. *Mol Cell*. 2015;59(5):835-849. https://doi.org/10.1016/j.molcel.2015.07.018

10. **Sansregret L, Swanton C.** The role of aneuploidy in cancer evolution. *Cold Spring Harb Perspect Med*. 2017;7(1):a028373. https://doi.org/10.1101/cshperspect.a028373

11. **Elowe S, Hümmer S, Uldschmid A, et al.** Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. *Genes Dev*. 2007;21(17):2205-2219. https://doi.org/10.1101/gad.436007

12. **Klebig C, Korinth D, Meraldi P.** Bub1 regulates chromosome segregation in a kinetochore-independent manner. *J Cell Biol*. 2009;186(6):841-858. https://doi.org/10.1083/jcb.200902128

13. **Guo Y, Kim C, Ahmad S, et al.** BUBR1 is required for the mitotic checkpoint and chromosome congression in human cells. *Proc Natl Acad Sci USA*. 2012;109(52):E3591-E3599. https://doi.org/10.1073/pnas.1217336109

14. **Baker DJ, Dawlaty MM, Wijshake T, et al.** Increased expression of BubR1 protects against aneuploidy and cancer and extends lifespan. *Nat Cell Biol*. 2013;15(1):96-102. https://doi.org/10.1038/ncb2643

15. **Matsumoto T, Yamada K, Ohta T, et al.** BUB1B overexpression is associated with poor prognosis in hepatocellular carcinoma. *Cancer Sci*. 2019;110(8):2488-2497. https://doi.org/10.1111/cas.14089

16. **Sotillo R, Schvartzman JM, Socci ND, et al.** Mad2-induced chromosome instability leads to lung tumour formation after oncogene-induced senescence. *Cancer Cell*. 2010;18(4):353-366. https://doi.org/10.1016/j.ccr.2010.09.004

17. **Silk AD, Holland AJ, Cleveland DW.** Requirements for CENP-E and BUBR1 in the spindle checkpoint and chromosome congression. *J Cell Sci*. 2013;126(Pt 13):2801-2811. https://doi.org/10.1242/jcs.121392

18. **Han J, Zhang G, Zhang Y, et al.** BUBR1 pseudokinase domain functions as a scaffold for MAD2 and CDC20 in the mitotic checkpoint. *J Biol Chem*. 2018;293(19):7320-7331. https://doi.org/10.1074/jbc.RA118.002456

19. **Sasaki M, Okada M, Kato T, et al.** HPV E7 degrades BUBR1 to induce chromosomal